ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein
Authors:
- 29 October 2011
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 69 (3) , 799-805
Abstract
Purpose Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent due to its selective cytotoxicity to transformed cells. However, most human hepatocellular carcinomas (HCC) develop resistance to TRAIL. Thus, there is an urgent need to investigate the molecular targets and the underlying mechanisms that may be involved in overriding the resistance of tumor cells to TRAIL. Methods Cell viability analysis was performed in HCC cells after treatment with TRAIL and/or ABT-263. Flow cytometry was used to assess apoptosis. The expression of caspases and members of the Bcl-2 family was examined through immunoblot analysis. Finally, the viability of cancer cells transfected with a plasmid containing HBx (hepatitis B virus X protein) following treatment with TRAIL was also measured. Results In this study, we demonstrate that ABT-263, a potent and orally bioavailable inhibitor of the Bcl-2 family, was able to reverse the resistance of hepatocarcinoma cell lines to TRAIL-induced apoptosis, while sparing normal liver cells. The molecular mechanism of the reversal in resistance may be attributed to the inhibition by ABT-263 of anti-apoptosis proteins of the Bcl-2 family. In addition, we determined that HBx was able to sensitize TRAIL-resistant hepatocarcinoma Huh7 cells. Conclusions These findings provide a novel insight into the clinical application of TRAIL-induced apoptosis of HCC cells.Keywords
This publication has 34 references indexed in Scilit:
- Molecularly targeted therapy for hepatocellular carcinoma from the basic and clinical aspectsInternational Journal of Clinical Oncology, 2010
- TRAIL-induced apoptosis of hepatocellular carcinoma cells isaugmented by targeted therapiesWorld Journal of Gastroenterology, 2009
- ABT-737 Induces Expression of the Death Receptor 5 and Sensitizes Human Cancer Cells to TRAIL-induced ApoptosisJournal of Biological Chemistry, 2008
- The BCL-2 protein family: opposing activities that mediate cell deathNature Reviews Molecular Cell Biology, 2008
- Malignant ascites protect against TRAIL‐induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cellsInternational Journal of Cancer, 2007
- Hepatocellular Carcinoma: Epidemiology and Molecular CarcinogenesisGastroenterology, 2007
- The Bcl-2 apoptotic switch in cancer development and therapyOncogene, 2007
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999
- Trypan Blue Exclusion Test of Cell ViabilityCurrent Protocols in Immunology, 1997
- Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine FamilyJournal of Biological Chemistry, 1996